2019/10/09
Keio University
AstraZeneca K.K.
Keio University (location: Minato-ku, Tokyo; President: Akira Haseyama) and AstraZeneca K.K. (headquarters: Kita-ku, Osaka; Representative Director and President: Stefan Woxström; hereinafter, "AstraZeneca") have signed a joint research agreement to generate Real-World Evidence (RWE) in the cardiovascular, renal, and metabolism disease area (hereinafter, "the disease area") by utilizing administrative healthcare data. They have agreed to aim to contribute to effective healthcare policies tailored to regional characteristics through industry-academia collaboration.
This joint research is one of the projects led by Keio University that aims to create life innovation by utilizing "PeOPLe," a people-centric information platform. This project has been selected for the Program on Open Innovation Platform with Enterprises, Research Institute and Academia (OPERA) by the Japan Science and Technology Agency (JST) (managed by: Tonomachi Town Campus). AstraZeneca will leverage its global experience in RWE research to collaborate with Keio University. Through this joint research, both parties will explore the development and advancement of fundamental technologies to accurately acquire administrative healthcare databases, including diverse medical claims (shinryo hoshu meisaisho) that also cover long-term care, as well as their utilization from the perspectives of understanding and preventing epidemiology and disease burden, and improving the allocation of medical resources in the disease area.
Please see below for the full press release.